EBTATE incorporates Evans Blue (EB) in the somatostatin analog backbone which significantly increases residence in albumin, a virtual slow release system. Conjugating a targeting molecule to Evans Blue (EB =albumin-binding motif) prolongs half-life in blood, enhancing theranostic bioavailability. In a head-to-head comparison, long-acting EBTATE showed favorable in vivo pharmacokinetics and anti-tumor efficacy vs. TATE.
